Phase 2 study of HP802-247 for venous leg ulcers

Healthpoint announced that it has initiated a Phase 2 clinical trial investigating the efficacy of HP802-247 in venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts that are sprayed sequentially on the wound bed at the time of treatment. The study is designed to determine the effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to placebo plus standard care, in healing venous leg ulcers over a 12-week treatment period.

For more information call (800) 441-8227 or visit www.healthpoint.com.